TP53 and neoplasm: Gene therapy, targeted tumor vaccines, and anti-cancer drugs targeting TP53 mutations are in the early stages of clinical trials, including APR-246 (eprenetapopt, PRIMA-1MET), PEITC (phenethyl isothiocyanate), ATO (arsenic trioxide/Trisenox), HSP90 inhibitor (ganetespib/STA-9090), Atorvastatin, Vorinostat/Zolinza/SAHA, Wee1 inhibitor (adavosertib/AZD1775/MK-1775), Lamivudine (3TC/Epivir/Zeffix/DELSTRIGO), Zoledronic acid (ZA/Reclast/Zometa), and atorvastatin [66,67].